Drugs / Proscavax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03579654 | Feb 2019 → Feb 2021 | prostate cancer | OncBioMune Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Proscavax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03579654 ↗ |
| Modality | Vaccine | “Proscavax is a prostate cancer vaccine” NCT03579654 ↗ |